Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan

ResMed's Chief Financial Officer, Brett Sandercock, executed a sale of 1,000 shares of ResMed common stock at a price of $215.58 per share on April 8, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 8, 2025, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
• The sale was executed at a price of $215.58 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
• Following the transaction, Sandercock directly owns 89,864 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of insider trading. The market typically views these sales in the context of the overall holdings of the insider and the reasons behind the sale, which are not always disclosed.

Comparison to Industry Standards

• Insider sales are a regular part of executive compensation and portfolio management across the industry.
• Companies like Medtronic, Stryker, and Philips also see regular insider trading activity.
• The volume and frequency of these trades are generally compared against the executive's total holdings and the company's overall performance.

Stakeholder Impact

• The sale of shares by a key executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the executive's remaining stake in the company.
• However, given the pre-planned nature of the sale under a 10b5-1 plan, the impact is likely to be minimal.

Key Dates

Keywords

ResMed, Brett Sandercock, CFO, Form 4, Share Sale, 10b5-1 Plan, RMD, Securities